^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT3 V592A

    i
    Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
    Entrez ID:
    2322
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    2years
    Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML) (ASH 2022)
    Compared with FLT3-ITD, Y572C, V592A and V592A conferred high sensitivity to gilteritinib (Fig...Notably, JMD muts were also sensitive to quizartinib and sorafenib, whereas TKD muts are not...In vitro, the most common FLT3-JMD point muts confer a transforming potential to hematopoietic cells as predicted, and our data suggest that pts carrying FLT3-JMD point muts could respond to treatment with available FLT3 inhibitors. Finally, in contrast to TKD, JMD mutant cells are sensitive to type 2 FLT3 inhibitors, expanding the scope of treatment options for these pts.
    Clinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1)
    |
    FLT3 mutation • FLT3 V592A
    |
    sorafenib • Xospata (gilteritinib) • Vanflyta (quizartinib)